Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
about
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisA Systematic Review of Methods for Handling Missing Variance Data in Meta-Analyses of Interventions in Type 2 Diabetes Mellitus.Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysisUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetesEfficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trialsA post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin.Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.The renal effects of SGLT2 inhibitors and a mini-review of the literature.The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Dapagliflozin combination therapy in type 2 diabetes mellitus.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.SGLT2 Inhibitors: Benefit/Risk Balance.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
P2860
Q26782225-450C5B9A-7B32-494B-B295-13232EB88161Q28553482-453C3505-D8D5-4811-92BA-82144294F608Q31137238-ECAC4D91-9ECF-4BB5-B204-5A08336C2F16Q33767478-9E29E8D5-56AA-462A-9FFE-767C7DC65607Q34198692-20D3EB3B-2310-4EF5-BE07-D1077152DD18Q35157497-B9974619-96BE-4584-A450-2A4081A85032Q35260544-DCD6D185-8AD7-40F7-A59D-26F82E7C51D6Q36096350-546D4938-C806-4A5C-BBEE-34DDC7905D9AQ36169413-1ACDCE7B-1D42-417F-9F07-4C6103314168Q36257565-16857F7D-4525-4598-84A9-5F92D326D5E9Q36361872-E34CFF32-EFDF-410A-9AC2-4E3C0864C35EQ37588847-16C78F5B-D94E-41B9-B661-BEA731DEA72BQ37632127-45611846-6F69-4771-B8D8-EF64327A1B65Q38215995-E7356B2A-62C3-4F76-9E1F-4804D692485BQ38389823-F52D7A25-F1E1-4B6D-BBA8-F1E87CBE5317Q38602771-F18C14A6-D8F5-4AE7-AFA4-AA900FA364E9Q38619164-6CE8E212-052C-4F0A-B4FF-2ADAF5571482Q38634051-FBBE71BB-79F9-406C-ADFE-5F4069DC6354Q38663903-BEAF8B6F-5780-4E6A-A487-4253770993D6Q38777020-D05B0C1A-E658-489D-9CDE-92C7BE14BEFDQ38796262-B5916BA2-9269-4EF9-8012-A40312261C93Q38931842-86A55B70-8A3F-4229-A4BA-E01E7AF6897CQ38936746-23474A94-76BB-4267-9CA8-15720D0097ABQ39007677-F775431C-A782-4A3E-84D2-538B9E90DD27Q39170860-CE4715DB-37B7-4F3D-A86C-C250B5892AA8Q47109328-CE861C1B-BAB4-4962-AB98-180F43B5557FQ47115045-DF355054-5593-44D9-B358-832A7BC942A6Q48130954-7E72213D-220F-4B58-9B89-233B0AD05192Q53633169-0C4B862F-7731-49B5-8259-1FD8A0206A94
P2860
Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sodium glucose co-transport 2 ...... double-blind controlled trials
@ast
Sodium glucose co-transport 2 ...... double-blind controlled trials
@en
type
label
Sodium glucose co-transport 2 ...... double-blind controlled trials
@ast
Sodium glucose co-transport 2 ...... double-blind controlled trials
@en
prefLabel
Sodium glucose co-transport 2 ...... double-blind controlled trials
@ast
Sodium glucose co-transport 2 ...... double-blind controlled trials
@en
P2860
P356
P1476
Sodium glucose co-transport 2 ...... double-blind controlled trials
@en
P2093
Alex Barker
P2860
P2888
P356
10.1186/1472-6823-13-58
P50
P577
2013-12-17T00:00:00Z
P5875
P6179
1044937645